IVIG Treatment Response and Age are Important for the Prognosis of Pediatric Immune Thrombocytopenia
10.15264/cpho.2022.29.2.44
- Author:
Min Gi SAKONG
1
;
Ji Hoon PARK
;
Sang Beom SON
;
Yu Kyung KIM
;
Jae Min LEE
Author Information
1. Department of Medicine, College of Medicine, Yeungnam University, Daegu, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Clinical Pediatric Hematology-Oncology
2022;29(2):44-51
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:This study aimed to identify chronicity predictors of pediatric primary immune thrombocytopenia (ITP).
Methods:This study retrospectively reviewed the medical records of patients with primary pediatric ITP admitted to a tertiary medical center between 2010 and 2021.Forty-five patients with a platelet count ＜20,000/L at the time of diagnosis who were treated with intravenous immunoglobulin (IVIG) were enrolled in this study.
Results:According to the disease phase, 28, 6, and 11 patients were classified into the newly diagnosed (ND), persistent, and chronic groups, respectively. The number of patients over 6 years of age was significantly higher in the chronic group than in the ND and persistent groups. After 14 days of IVIG treatment, more patients had a complete response in the non-chronic groups than in the chronic group. In univariate analysis of risk factor for chronic ITP, age 6 years or older and IVIG dose ＜2 g/kg were found to be risk factors for chronic ITP, and these two factors were also confirmed as significant risk factors in multivariate analysis.
Conclusion:In conclusion, in our study, patients over 6 years of age, and those who received IVIG doses less than 2 g/kg were more likely to progress to chronic ITP.
